Updated:
Biossom Investment Management
Biossom Investment Management is a venture capital fund focused on bio-pharmaceuticals investments. It has made 12 investments, including a Series A - II...
Biossom Investment Management
Biossom Investment Management is a venture capital fund focused on bio-pharmaceuticals investments. It has made 12 investments, including a Series A - II investment in Pharmcube on September 17, 2018. The firm has 5 portfolio exits, with Biostar being its most recent exit on October 31, 2024.
General information
Firm type
Private Equity
Year founded
2012
Location
Region
Asia
Country
China
City
Beijing
Corporate office
Beijing, China
Frequently asked questions
What investment stages does Biossom Investment Management target?
Biossom covers a full venture lifecycle: early-stage seed and startup rounds, plus expansion and late-stage growth capital. The firm categorizes this as generalist venture, meaning it does not restrict itself to a single-point entry and can follow portfolio companies through multiple funding rounds. This multi-stage approach is documented in the firm's own strategy disclosures.
Where is Biossom Investment Management's geographic focus?
The firm is headquartered in Beijing and concentrates its investment activity within China. No additional offices or cross-border mandates have been identified in public record. The single-jurisdiction focus aligns with the deep-local sourcing required for competitive early-stage venture in the Chinese market.
What is Biossom's known posture on co-investments alongside external GPs?
Public record does not detail Biossom's co-investment practices. For a venture-stage firm of its profile in Beijing, co-investment typically depends on deal-by-deal syndicate formation rather than a formalized separate co-investment vehicle. No public syndication records or GP-relationship disclosures are available to confirm active practice.
How does Biossom Investment Management source its deal flow?
The firm's absence of a public website or LinkedIn presence suggests relationship-based sourcing rather than a broad institutional marketing approach. In China's venture ecosystem, this often means direct founder networks, university pipelines, and referrals from portfolio company executives—though specific sourcing channels are not publicly disclosed by the firm.
Is Biossom structured as a family office or a traditional venture firm?
Biossom is categorized as an asset manager operating a private equity strategy, not a single-family office. The firm's multi-stage venture mandate and Beijing headquarters suggest a pooled-capital vehicle rather than a dedicated family wealth manager. No public information confirms the identity of any single family or patronage structure.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: